<\/p>\n
Invokana<\/strong> je zna\u010dka canagliflozin<\/strong> (100 mg nebo 300 mg), inhibitor SGLT-2<\/strong> (\u201cgliflozin\u201d) pou\u017e\u00edvan\u00fd p\u0159i cukrovce 2. typu, srde\u010dn\u00edm selh\u00e1n\u00ed a chronick\u00e9m onemocn\u011bn\u00ed ledvin (CKD)<\/strong>. P\u016fsob\u00ed blokov\u00e1n\u00edm reabsorpce gluk\u00f3zy v ledvin\u00e1ch, co\u017e vede k vylu\u010dov\u00e1n\u00ed 70\u201390 g gluk\u00f3zy denn\u011b mo\u010d\u00ed. T\u00edm sni\u017euje hladinu gluk\u00f3zy v krvi nez\u00e1visle na inzul\u00ednu, zp\u016fsobuje \u00fabytek hmotnosti o 2\u20133 kg, pokles krevn\u00edho tlaku o 3\u20135 mmHg a \u2013 v\u00fdjime\u010dn\u011b mezi antidiabetiky \u2013 sni\u017euje hospitalizace pro srde\u010dn\u00ed selh\u00e1n\u00ed a zpomaluje progresi chronick\u00e9ho onemocn\u011bn\u00ed ledvin (CKD) u pacient\u016f s diabetem i bez n\u011bj. Sn\u00ed\u017een\u00ed HbA1c: 0,6\u20130,9 procentn\u00edch bod\u016f. D\u00e1vkov\u00e1n\u00ed: 100 mg jednou denn\u011b p\u0159ed prvn\u00edm j\u00eddlem dne. D\u00e1vku lze zv\u00fd\u0161it na 300 mg\/den, pokud kontrola glyk\u00e9mie nen\u00ed dostate\u010dn\u00e1 a eGFR > 60. Pro indikace CKD\/CV: 100 mg\/den. Nezp\u016fsobuje hypoglyk\u00e9mii<\/strong> jako monoterapie. Hlavn\u00ed rizika: genit\u00e1ln\u00ed kandid\u00f3za (\u010dast\u00e1, m\u00edrn\u00e1), infekce mo\u010dov\u00fdch cest, vz\u00e1cn\u011b diabetick\u00e1 ketoacid\u00f3za (n\u011bkdy s t\u00e9m\u011b\u0159 norm\u00e1ln\u00ed hladinou gluk\u00f3zy \u2013 \u201ceuglykemick\u00e1 DKA\u201d) a sn\u00ed\u017een\u00ed objemu tekutin. Nevhodn\u00e9 pro diabetes 1. typu.<\/p>\n<\/div>\n \ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n Invokana je peror\u00e1ln\u00ed inhibitor SGLT-2 (sodno-gluk\u00f3zov\u00e9ho kotransport\u00e9ru-2) obsahuj\u00edc\u00ed canagliflozin<\/strong> (100 mg nebo 300 mg), vyr\u00e1b\u011bn\u00fd spole\u010dnost\u00ed Janssen \/ Johnson & Johnson. Dostupn\u00e9 v balen\u00edch po 30, 60, 90 nebo 180 tablet\u00e1ch. Je schv\u00e1len pro:<\/p>\n Canagliflozin byl poprv\u00e9 schv\u00e1len v roce 2013 (origin\u00e1ln\u00ed zna\u010dka: Invokana, Janssen \/ Johnson & Johnson). Je to jedna z klinicky nejv\u00fdznamn\u011bj\u0161\u00edch t\u0159\u00edd antidiabetik v posledn\u00edm desetilet\u00ed, proto\u017ee stejn\u00fd l\u00e9k sou\u010dasn\u011b l\u00e9\u010d\u00ed t\u0159i nej\u010dast\u011bj\u0161\u00ed dlouhodob\u00e9 komplikace diabetu.<\/p>\n Zdrav\u00e9 ledviny denn\u011b profiltruj\u00ed 180 g gluk\u00f3zy p\u0159es glomeruly a t\u00e9m\u011b\u0159 v\u0161echnu ji zp\u011btn\u011b vst\u0159ebaj\u00ed do krevn\u00edho \u0159e\u010di\u0161t\u011b prost\u0159ednictv\u00edm transport\u00e9ru SGLT-2 v proxim\u00e1ln\u00edm tubulu. U diabetu je tato reabsorpce ve skute\u010dnosti zes\u00edlena<\/em> \u2013 t\u011blo zadr\u017euje v\u00edce gluk\u00f3zy pr\u00e1v\u011b tehdy, kdy\u017e by ji m\u011blo \u010d\u00e1st uvolnit.<\/p>\n Canagliflozin selektivn\u011b blokuje SGLT-2, co\u017e vede k vylu\u010dov\u00e1n\u00ed 70\u201390 g gluk\u00f3zy denn\u011b mo\u010d\u00ed. T\u00edm:<\/p>\n canagliflozin m\u00e1 v\u00fdjime\u010dn\u011b robustn\u00ed data z v\u00fdsledkov\u00fdch studi\u00ed:<\/p>\n Tyto studie zm\u011bnily praxi: inhibitory SGLT-2 jsou nyn\u00ed doporu\u010dov\u00e1ny pro v\u0161echny pacienty s diabetem 2. typu, kte\u0159\u00ed maj\u00ed prok\u00e1zan\u00e9 kardiovaskul\u00e1rn\u00ed onemocn\u011bn\u00ed, srde\u010dn\u00ed selh\u00e1n\u00ed nebo chronick\u00e9 onemocn\u011bn\u00ed ledvin \u2014 bez ohledu na hodnotu HbA1c.<\/p>\n Standardn\u00ed d\u00e1vka:<\/strong> 100 mg jednou denn\u011b p\u0159ed prvn\u00edm j\u00eddlem dne. D\u00e1vku lze zv\u00fd\u0161it na 300 mg\/den, pokud nen\u00ed dosa\u017eeno adekv\u00e1tn\u00ed kontroly glyk\u00e9mie a eGFR > 60. Pro indikace CKD\/kardiovaskul\u00e1rn\u00ed onemocn\u011bn\u00ed: 100 mg\/den.<\/p>\n \u010cast\u00e9:<\/strong><\/p>\n M\u00e9n\u011b \u010dast\u00e9, ale d\u016fle\u017eit\u00e9:<\/strong><\/p>\n Skladujte Invokana p\u0159i teplot\u011b pod 30\u00b0C na such\u00e9m m\u00edst\u011b, v p\u016fvodn\u00edm blistru. Uchov\u00e1vejte mimo dosah d\u011bt\u00ed.<\/p>\n Ano \u2014 Invokana obsahuje canagliflozin jako \u00fa\u010dinnou l\u00e1tku. Regula\u010dn\u00ed org\u00e1ny vy\u017eaduj\u00ed bioekvivalenci, tak\u017ee klinick\u00fd \u00fa\u010dinek je p\u0159i stejn\u00e9 d\u00e1vce stejn\u00fd.<\/p>\n Sign\u00e1l zv\u00fd\u0161en\u00e9ho rizika amputac\u00ed poch\u00e1z\u00ed z programu CANVAS (absolutn\u00ed riziko 6,3 vs 3,4 na 1000 pacient\u016f za rok). Tento sign\u00e1l nebyl pozorov\u00e1n ve studii CREDENCE ani ve v\u011bt\u0161in\u011b re\u00e1ln\u00fdch studi\u00ed a FDA v roce 2020 odstranila svou \u010dernou v\u00fdstrahu. V\u011bt\u0161ina klinik\u016f nyn\u00ed pova\u017euje canagliflozin za bezpe\u010dn\u00fd pro pacienty bez p\u0159edchoz\u00ed amputace, aktivn\u00edho v\u0159edu na noze nebo t\u011b\u017ek\u00e9 perifern\u00ed arteri\u00e1ln\u00ed choroby. U v\u0161ech inhibitor\u016f SGLT-2 se doporu\u010duje kontrola nohou a hygiena obuvi.<\/p>\n Ano, m\u00edrn\u011b \u2014 obvykle \u00fabytek 2\u20133 kg za 6\u201312 m\u011bs\u00edc\u016f. \u00dabytek v\u00e1hy je zp\u016fsoben t\u00edm, \u017ee va\u0161e ledviny vylu\u010duj\u00ed 70\u201390 g gluk\u00f3zy (~280\u2013320 kcal) denn\u011b mo\u010d\u00ed. Jde o re\u00e1ln\u00fd, ale omezen\u00fd efekt \u2014 neo\u010dek\u00e1vejte dramatick\u00e9 \u00fa\u010dinky jako u agonist\u016f GLP-1 receptor\u016f, nap\u0159\u00edklad semaglutidu (Ozempic, Wegovy) nebo tirzepatidu (Mounjaro).<\/p>\n Ano \u2014 o\u010dek\u00e1vejte pokles systolick\u00e9ho tlaku asi o 3\u20135 mmHg. Pokud ji\u017e u\u017e\u00edv\u00e1te l\u00e9ky na tlak a m\u00e1te hodnoty bl\u00edzko c\u00edlov\u00fdch, mo\u017en\u00e1 budete pot\u0159ebovat sn\u00ed\u017eit d\u00e1vku p\u0159i zah\u00e1jen\u00ed u\u017e\u00edv\u00e1n\u00ed Invokany, abyste p\u0159ede\u0161li z\u00e1vrat\u00edm.<\/p>\n Ano \u2014 genit\u00e1ln\u00ed kvasinkov\u00e1 infekce je nej\u010dast\u011bj\u0161\u00edm vedlej\u0161\u00edm \u00fa\u010dinkem (a\u017e u 10 % u\u017eivatel\u016f, p\u0159ev\u00e1\u017en\u011b \u017een). Obvykle je m\u00edrn\u00e1 a snadno se l\u00e9\u010d\u00ed lok\u00e1ln\u00edmi nebo peror\u00e1ln\u00edmi antimykotiky. Infekce mo\u010dov\u00fdch cest jsou m\u00edrn\u011b \u010dast\u011bj\u0161\u00ed, ale v\u011bt\u0161inou nekomplikovan\u00e9. D\u016fle\u017eit\u00e1 je hygiena; v\u011bt\u0161ina pacient\u016f nemus\u00ed l\u00e9k vysadit.<\/p>\n Ano \u2014 a ve skute\u010dnosti SGLT-2 inhibitory chr\u00e1n\u00ed<\/em> ledviny p\u0159i chronick\u00e9m onemocn\u011bn\u00ed ledvin (CKD). Po\u010d\u00e1te\u010dn\u00ed limity se li\u0161\u00ed podle molekuly (viz \u010d\u00e1st o d\u00e1vkov\u00e1n\u00ed p\u0159i ren\u00e1ln\u00ed insuficienci), ale po zah\u00e1jen\u00ed l\u00e9\u010dby se obvykle pokra\u010duje a\u017e do dial\u00fdzy, proto\u017ee ochrann\u00fd \u00fa\u010dinek na ledviny p\u0159etrv\u00e1v\u00e1, i kdy\u017e \u00fa\u010dinek na sn\u00ed\u017een\u00ed glyk\u00e9mie sl\u00e1bne.<\/p>\n P\u0159i akutn\u00edm onemocn\u011bn\u00ed s dehydratac\u00ed, zvracen\u00edm nebo sn\u00ed\u017een\u00fdm p\u0159\u00edjmem tekutin a p\u0159ed v\u011bt\u0161\u00ed operac\u00ed nebo b\u011bhem p\u016fstu Invokanu do\u010dasn\u011b vysa\u010fte. T\u00edm sn\u00ed\u017e\u00edte riziko euglykemick\u00e9 ketoacid\u00f3zy a akutn\u00edho po\u0161kozen\u00ed ledvin. Znovu ji za\u010dn\u011bte u\u017e\u00edvat, a\u017e budete norm\u00e1ln\u011b j\u00edst a p\u00edt.<\/p>\n Invokana (100 mg nebo 300 mg) si m\u016f\u017eete objednat na MedsBase v balen\u00edch po 30, 60, 90 nebo 180 tablet\u00e1ch. Dod\u00e1v\u00e1me po cel\u00e9m sv\u011bt\u011b, s diskr\u00e9tn\u00edm balen\u00edm a z\u00e1sobami od ov\u011b\u0159en\u00fdch v\u00fdrobc\u016f s certifikac\u00ed WHO-GMP.<\/p>\n <\/p>\n Dal\u0161\u00ed produkty v Chronick\u00e1 onemocn\u011bn\u00ed<\/strong> kter\u00e9 z\u00e1kazn\u00edci tak\u00e9 prohl\u00ed\u017eej\u00ed:<\/p>\n \u2705 Reguluje hladinu cukru v krvi Invokana obsahuje canagliflozin<\/span><\/p>","protected":false},"featured_media":55131,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3230,3231],"product_tag":[3866,3867],"class_list":{"0":"post-55130","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-diabetes","9":"product_cat-diabetes-medication","10":"product_tag-canagliflozin","11":"product_tag-invokana","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/55130","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=55130"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/55131"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=55130"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=55130"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=55130"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=55130"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n
Co je Invokana?<\/h2>\n
\n
Jak funguje Invokana?<\/h2>\n
\n
Kardiovaskul\u00e1rn\u00ed, srde\u010dn\u00ed a ren\u00e1ln\u00ed benefity<\/h2>\n
\n
D\u00e1vkov\u00e1n\u00ed a pod\u00e1n\u00ed<\/h2>\n
\n
Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n
\n
\n
Interakce s l\u00e9\u010divy<\/h2>\n
\n
Kdo by nem\u011bl u\u017e\u00edvat Invokana?<\/h2>\n
\n
Skladov\u00e1n\u00ed<\/h2>\n
\u010casto kladen\u00e9 dotazy<\/h2>\n
Je Invokana tot\u00e9\u017e co canagliflozin?<\/h3>\n
Je canagliflozin bezpe\u010dn\u00fd \u2014 co riziko amputace?<\/h3>\n
Pom\u016f\u017ee mi Invokana zhubnout?<\/h3>\n
Sn\u00ed\u017e\u00ed Invokana m\u016fj krevn\u00ed tlak?<\/h3>\n
M\u016f\u017ee Invokana zp\u016fsobit kvasinkovou infekci nebo UTI?<\/h3>\n
M\u016f\u017eu u\u017e\u00edvat Invokanu, pokud m\u00e1m sn\u00ed\u017eenou funkci ledvin?<\/h3>\n
Co m\u00e1m d\u011blat p\u0159i nemoci nebo p\u0159ed operac\u00ed?<\/h3>\n
Kde si mohu koupit Invokanu online?<\/h3>\n
Souvisej\u00edc\u00ed l\u00e9ky na diabetes<\/h2>\n
\n
Souvisej\u00edc\u00ed alternativy<\/h3>\n
\n
\n\u2705 Sni\u017euje riziko srde\u010dn\u00edch onemocn\u011bn\u00ed
\n\u2705 Podporuje Hubnut\u00ed<\/a>
\n\u2705 Sni\u017euje krevn\u00ed tlak<\/a>
\n\u2705 Zlep\u0161uje zdrav\u00ed ledvin<\/p>\n